A novel prodrug of epigallocatechin-3-gallate: Differential epigenetic hTERT repression in human breast cancer cells

Cancer Prevention Research

Volumn 4, Issue 8, 2011, Pages 1243-1254

  Meeran, Syed M ^a   Patel, Shweta N ^a   Chan, Tak Hang ^b   Tollefsbol, Trygve O ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR; HISTONE ACETYLTRANSFERASE; TELOMERASE REVERSE TRANSCRIPTASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; CHROMATIN STRUCTURE; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; EPIGENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; FEMALE; FLOW CYTOMETRY; HISTONE ACETYLTRANSFERASES; HUMANS; PRODRUGS; PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 80051520893     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0009     Document Type: Article

References (46)

1. Roy AM, Baliga MS, Katiyar SK. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther 2005;4:81-90. (Pubitemid 40268069)
2. Sadava D, Whitlock E, Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drugresistant lung cancer cells. Biochem Biophys Res Commun 2007;360:233-7. (Pubitemid 46994711)
3. Tran PL, Kim SA, Choi HS, Yoon JH, Ahn SG. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits antitumor activity in vitro and in vivo. BMC Cancer 2010;10:276.
4. Mittal A, Pate MS, Wylie RC, Tollefsbol TO, Katiyar SK. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int J Oncol 2004;24:703-10.
5. Lin J, Liang Y. Cancer chemoprevention by tea polyphenols. Proc Natl Sci Counc Repub China B 2000;24:1-13.
6. Ahmad N, Feyes D, Nieminen A, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997;89:1881-6. (Pubitemid 28009824)
7. Gu B, Ding Q, Xia G, Fang Z. EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression. Oncol Rep 2009;21:635-40.
8. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-5.
9. Fassina G, Venè R, Morini M, Minghelli S, Benelli R, Noonan D, et al. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 2004;10:4865-73. (Pubitemid 38955541)
10. Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenet 2010;1:101-16.
11. Cunningham AP, Love WK, Zhang RW, Andrews LG, Tollefsbol TO. Telomerase inhibition in cancer therapeutics: molecular-based approaches. Curr Med Chem 2006;13:2875-88. (Pubitemid 44509713)
12. Liu L, Lai S, Andrews L, Tollefsbol T. Genetic and epigenetic modulation of telomerase activity in development and disease. Gene 2004;340:1-10. (Pubitemid 39360227)
13. Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 1998;249:391-6. (Pubitemid 28431764)
14. Fang M, Chen D, Yang C. Dietary polyphenols may affect DNA methylation. J Nutr 2007;137:223S-8S.
15. Fang M, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-70. (Pubitemid 37466673)
16. Choi KC, Jung MG, Lee YH, Yoon JC, Kwon SH, Kang HB, et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res 2009;69:583-92.
17. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 2008;99:1528-38.
18. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman F, Lobanenkov V, et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 2007;35:1245-56. (Pubitemid 46522976)
19. Ge Z, Li W, Wang N, Liu C, Zhu Q, Björkholm M, et al. Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J 2010;24:579-86.
20. Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem 2008;103:509-19. (Pubitemid 351171921)
21. Günes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res 2000;60:2116-21. (Pubitemid 30225170)
22. Xu D, Popov N, Hou M, Wang Q, Björkholm M, Gruber A, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A 2001;98:3826-31. (Pubitemid 32249856)
23. Crowe DL, Nguyen DC, Tsang KJ, Kyo S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res 2001;29:2789-94. (Pubitemid 32685042)
24. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, et al. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res. 2007;67:4303-10. (Pubitemid 46815078)
25. Lam WH, Kazi A, Kuhn DJ, Chow LM, Chan AS, Dou QP, et al. A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG]. Bioorg Med Chem 2004;12:5587-93. (Pubitemid 39304058)
26. Lambert JD, Sang S, Hong J, Kwon SJ, Lee MJ, Ho CT, et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos 2006;34:2111-6. (Pubitemid 44837773)
27. Meeran SM, Patel SN, Tollefsbol TO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One 2010;5:e11457.
28. Ciftci K, Su J, Trovitch P. Growth factors and chemotherapeutic modulation of breast cancer cells. J Pharm Pharmacol 2003;55:1135-41. (Pubitemid 36998655)
29. Golubovskaya V, Virnig C, Cance W. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 2008;47:222-34. (Pubitemid 351398065)
30. Meeran SM, Katiyar S, Katiyar SK. Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol 2008;229:33-43.
31. Li Y, Liu L, Andrews L, Tollefsbol T. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer 2009;125:286-96.
32. Wang P, Henning SM, Heber D. Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 2010;5:e10202.
33. Naasani I, Oh-Hashi F, Oh-Hara T, Feng W, Johnston J, Chan K, et al. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 2003;63:824-30. (Pubitemid 36231983)
34. Louie MC, McClellan A, Siewit C, Kawabata L. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res 2010;8:343-52.
35. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 2007;21:2112-23. (Pubitemid 47347376)
36. Nanni S, Narducci M, Della Pietra L, Moretti F, Grasselli A, De Carli P, et al. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest 2002;110:219-27. (Pubitemid 34787359)
37. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 2000;20:3764-71. (Pubitemid 30314476)
38. Zinn R, Pruitt K, Eguchi S, Baylin S, Herman J. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 2007;67:194-201. (Pubitemid 46142775)
39. Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008;68: 2736-44. (Pubitemid 351556271)
40. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 2008;123:552-60. (Pubitemid 351898412)
41. Cong YS, Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 2000;275:35665-8.
42. Oh S, Song YH, Yim J, Kim TK. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000;19: 1485-90. (Pubitemid 30171181)
43. Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, Yan PS, et al. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell 2006;21:393-404. (Pubitemid 43163534)
44. Yang H, Sun DK, Chen D, Cui QC, Gu YY, Jiang T, et al. Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs. Cancer Lett 2010;292:48-53.
45. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000;19:1020-7. (Pubitemid 30153785)
46. Rossi C, Di Lena A, La Sorda R, Lattanzio R, Antolini L, Patassini C, et al. Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer. Eur J Cancer 2008;44:2696-704.